Free Trial

Moleculin Biotech (MBRX) Competitors

$3.74
-0.04 (-1.06%)
(As of 06/21/2024 ET)

MBRX vs. VCNX, XLO, ACST, PMN, LSTA, BIVI, ENLV, NRXP, BOLT, and HCWB

Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Vaccinex (VCNX), Xilio Therapeutics (XLO), Acasti Pharma (ACST), ProMIS Neurosciences (PMN), Lisata Therapeutics (LSTA), BioVie (BIVI), Enlivex Therapeutics (ENLV), NRx Pharmaceuticals (NRXP), Bolt Biotherapeutics (BOLT), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.

Moleculin Biotech vs.

Moleculin Biotech (NASDAQ:MBRX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.

Moleculin Biotech presently has a consensus target price of $35.00, indicating a potential upside of 835.83%. Given Moleculin Biotech's higher possible upside, research analysts plainly believe Moleculin Biotech is more favorable than Vaccinex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moleculin Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vaccinex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Moleculin Biotech has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 6.7% of Moleculin Biotech shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Moleculin Biotech's return on equity of -87.19% beat Vaccinex's return on equity.

Company Net Margins Return on Equity Return on Assets
Moleculin BiotechN/A -87.19% -68.91%
Vaccinex N/A -2,667.31%-461.17%

In the previous week, Vaccinex's average media sentiment score of 0.98 beat Moleculin Biotech's score of 0.00 indicating that Vaccinex is being referred to more favorably in the news media.

Company Overall Sentiment
Moleculin Biotech Neutral
Vaccinex Positive

Vaccinex has higher revenue and earnings than Moleculin Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moleculin BiotechN/AN/A-$29.77MN/AN/A
Vaccinex$570K16.91-$20.25M-$82.80-0.07

Moleculin Biotech received 104 more outperform votes than Vaccinex when rated by MarketBeat users. However, 60.00% of users gave Vaccinex an outperform vote while only 52.91% of users gave Moleculin Biotech an outperform vote.

CompanyUnderperformOutperform
Moleculin BiotechOutperform Votes
227
52.91%
Underperform Votes
202
47.09%
VaccinexOutperform Votes
123
60.00%
Underperform Votes
82
40.00%

Summary

Moleculin Biotech and Vaccinex tied by winning 6 of the 12 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBRX vs. The Competition

MetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.64M$7.40B$5.35B$8.42B
Dividend YieldN/A2.76%2.83%4.09%
P/E RatioN/A12.15123.7215.24
Price / SalesN/A253.782,167.4069.36
Price / CashN/A32.0834.2430.94
Price / Book0.325.544.744.19
Net Income-$29.77M$147.49M$110.77M$216.41M
7 Day Performance-9.66%-2.05%-2.23%-1.22%
1 Month Performance-24.75%-5.21%-4.45%-3.90%
1 Year Performance-58.43%-8.88%-3.12%-0.31%

Moleculin Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCNX
Vaccinex
0 of 5 stars
$6.10
-3.5%
N/A-92.4%$9.64M$570,000.00-0.0737Gap Up
XLO
Xilio Therapeutics
0.3717 of 5 stars
$0.91
-5.2%
N/A-69.4%$33.53MN/A-0.3573Gap Down
ACST
Acasti Pharma
2.337 of 5 stars
$3.30
+4.8%
$6.00
+81.8%
-3.5%$31.02MN/A-0.6532Upcoming Earnings
News Coverage
PMN
ProMIS Neurosciences
1.4129 of 5 stars
$1.60
+3.2%
$8.00
+400.0%
-64.0%$30.34M$10,000.00-2.166Positive News
Gap Down
LSTA
Lisata Therapeutics
2.4385 of 5 stars
$3.53
+4.7%
$15.00
+324.9%
-9.5%$29.33MN/A-1.4325Gap Down
BIVI
BioVie
0.6714 of 5 stars
$0.47
+2.2%
$8.00
+1,603.9%
-92.0%$28.72MN/A-0.5018News Coverage
ENLV
Enlivex Therapeutics
2.9581 of 5 stars
$1.36
+3.0%
$6.00
+341.2%
-50.9%$28.38MN/A-0.9850Gap Up
NRXP
NRx Pharmaceuticals
1.6233 of 5 stars
$2.65
-8.6%
$43.00
+1,522.6%
-94.7%$28.36MN/A-0.842News Coverage
BOLT
Bolt Biotherapeutics
2.8163 of 5 stars
$0.75
+1.4%
$3.50
+366.7%
-48.3%$28.04M$11.32M-0.45100
HCWB
HCW Biologics
0 of 5 stars
$0.72
-27.9%
N/A-64.6%$27.34M$2.84M-0.9545Gap Down

Related Companies and Tools

This page (NASDAQ:MBRX) was last updated on 6/22/2024 by MarketBeat.com Staff

From Our Partners